A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

Frederick Stehman, J. A. Blessing, R. McGehee, R. J. Barrett

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol [DBD]). The drug was administered orally at an initial dose of 180 mg/m2 per day for 10 days and repeated every 4 weeks. There were 55 evaluable patients, of whom one (2%) had a complete response (CR), and 15 (27%) had a partial response (PR), (CR plus PR, 29%). A 95% confidence interval for the true response rate is 18.8% to 42.1%. Myelosuppression was appreciable at this dose and schedule, with 13 patients experiencing life-threatening thrombocytopenia and two drug-related deaths. The level of activity in this disease encourages us to determine a tolerable dose of this drug in combination with cisplatin for further study.

Original languageEnglish
Pages (from-to)1892-1895
Number of pages4
JournalJournal of Clinical Oncology
Volume7
Issue number12
StatePublished - 1989
Externally publishedYes

Fingerprint

Mitolactol
Cervix Uteri
Squamous Cell Carcinoma
Drug Combinations
Thrombocytopenia
Pharmaceutical Preparations
Cisplatin
Appointments and Schedules
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix : a Gynecologic Oncology Group study. / Stehman, Frederick; Blessing, J. A.; McGehee, R.; Barrett, R. J.

In: Journal of Clinical Oncology, Vol. 7, No. 12, 1989, p. 1892-1895.

Research output: Contribution to journalArticle

@article{921e798fe4074cd29f31b9e9595753db,
title = "A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study",
abstract = "Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol [DBD]). The drug was administered orally at an initial dose of 180 mg/m2 per day for 10 days and repeated every 4 weeks. There were 55 evaluable patients, of whom one (2{\%}) had a complete response (CR), and 15 (27{\%}) had a partial response (PR), (CR plus PR, 29{\%}). A 95{\%} confidence interval for the true response rate is 18.8{\%} to 42.1{\%}. Myelosuppression was appreciable at this dose and schedule, with 13 patients experiencing life-threatening thrombocytopenia and two drug-related deaths. The level of activity in this disease encourages us to determine a tolerable dose of this drug in combination with cisplatin for further study.",
author = "Frederick Stehman and Blessing, {J. A.} and R. McGehee and Barrett, {R. J.}",
year = "1989",
language = "English",
volume = "7",
pages = "1892--1895",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix

T2 - a Gynecologic Oncology Group study

AU - Stehman, Frederick

AU - Blessing, J. A.

AU - McGehee, R.

AU - Barrett, R. J.

PY - 1989

Y1 - 1989

N2 - Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol [DBD]). The drug was administered orally at an initial dose of 180 mg/m2 per day for 10 days and repeated every 4 weeks. There were 55 evaluable patients, of whom one (2%) had a complete response (CR), and 15 (27%) had a partial response (PR), (CR plus PR, 29%). A 95% confidence interval for the true response rate is 18.8% to 42.1%. Myelosuppression was appreciable at this dose and schedule, with 13 patients experiencing life-threatening thrombocytopenia and two drug-related deaths. The level of activity in this disease encourages us to determine a tolerable dose of this drug in combination with cisplatin for further study.

AB - Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol [DBD]). The drug was administered orally at an initial dose of 180 mg/m2 per day for 10 days and repeated every 4 weeks. There were 55 evaluable patients, of whom one (2%) had a complete response (CR), and 15 (27%) had a partial response (PR), (CR plus PR, 29%). A 95% confidence interval for the true response rate is 18.8% to 42.1%. Myelosuppression was appreciable at this dose and schedule, with 13 patients experiencing life-threatening thrombocytopenia and two drug-related deaths. The level of activity in this disease encourages us to determine a tolerable dose of this drug in combination with cisplatin for further study.

UR - http://www.scopus.com/inward/record.url?scp=0024790114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024790114&partnerID=8YFLogxK

M3 - Article

C2 - 2685182

AN - SCOPUS:0024790114

VL - 7

SP - 1892

EP - 1895

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -